Syngene International Ltd (SYNGENE) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Syngene International is a contract research, development and manufacturing organization (CRDMO) that provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods and agrochemical companies. Syngene’s clients are world leaders in their fields, ranging from leading global multinationals to small and medium-sized start-ups, non-profit institutions, academic institutes and government organizations.

Incorporated in 1993, Syngene is listed separately on the Indian stock exchanges - NSE and BSE. With a unique business model, a talent pool of scientists, scientific expertise across new therapeutic modalities, an experienced management team, and an independent Board committee, Syngene works for clients around the globe, delivering innovation that benefits human and animal health. As a strategic partner to its clients, often working as an extension of their internal scientific teams, Syngene offers innovative, flexible, and efficient approaches to scale up rapidly. This, in turn, enables faster go-to-market and access to patients.

Syngene’s focus on innovation is evident in its approach to integrated, end-to-end services that is spread across drug research, development and manufacturing capabilities covering the entire value chain. Its proprietary platform for integrated services (SynVent) provides an effective and efficient means to advance programs through target validation, translational interrogation, therapeutic discovery, and pre-clinical development for small molecules and biologics. Clients benefit from a faster, seamless R&D process, while the company can utilize its full breadth of resources.

Business area of the company

The company is a contract research, development, and manufacturing services company that offers a broad range of scientific services from the earliest stages of discovery to commercial supplies. This positions the Company as an end-to-end service provider within its sector. With skilled scientists, advanced technological capabilities and in-depth scientific expertise, Syngene stands out as a preferred partner for biopharmaceutical companies seeking integrated drug discovery, development and manufacturing services. Although its primary focus is on the pharmaceutical sector, Syngene also collaborates with companies in nutrition, animal health, consumer products, and specialty chemicals. 

Business divisions of the company 

Research services: Its Research Services division supports the full spectrum of early-stage R&D, from target identification to clinical transition. This integrated division brings together Discovery Chemistry, Discovery Biology, Translational & Clinical Research and Dedicated R&D Centers. Its dedicated R&D Centers offer a comprehensive solution for customers seeking large-scale research facilities without major long-term capital investment. These centers function as an extension of its customers’ internal research network, providing seamless integration while offering operational flexibility. Each center is staffed with a dedicated, multi-disciplinary team of scientists and support personnel, ensuring efficient project execution. Its expertise spans small molecules, biologics, and advanced modalities such as peptides, oligonucleotides, antibodydrug conjugates, and targeted protein degradation/ stabilization thus enabling end-to-end solutions that accelerate drug development.

Development services: Its Development Services division takes forward promising candidates from the Research Services pipeline, with a focus on small molecules. It provides end-to-end support from preclinical development through clinical trial readiness, specializing in drug substance and drug product development. Its capabilities ensure safety, tolerability, and efficacy through rigorous testing and validation. It also works with next-generation modalities, including antibody-drug conjugates (ADCs), oligonucleotides, and peptides, ensuring a smooth, science-driven transition from development to GMP-compliant manufacturing with a focus on efficiency and sustainability. Additionally, it works with performance chemicals and specialty materials, leveraging expertise in synthetic, organic and polymer chemistry. Integrated analytical services support every stage of development, covering method development, validation, transfer, and reference standard qualification.

Contract Development and Manufacturing Services (CDMO): The company’s CDMO Services specialize in the development, scale-up and manufacturing of drug products for clinical trials and commercial distribution. They offer a range of services that include drug development, process development, analytical testing, formulation development, scale-up, manufacturing, packaging and distribution. These services can be provided on a standalone basis, or as part of a complete end-to-end service offering.

Small Molecule CDMO: Small molecule manufacturing is carried out at its USFDA-compliant API facility in Mangaluru, ensuring high-quality and regulatory-compliant production.

Large Molecule CDMO: Large molecule development and manufacturing take place at its biologics facility in Bengaluru, which is approved by U.S. and European regulatory authorities. Additionally, it has a multimodal biologics manufacturing facility. To strengthen its global biologics capacity, it recently acquired a state-of-the-art manufacturing facility in the United States, expanding its ability to serve customers across regions with greater flexibility and scale.

Awards and accolades 

• 2000-01: Certificate of Excellence for Export Achievement - Under 100% EOU Scheme in Karnataka.
• 2001-02: Certificate of Excellence for Export Achievement - Under 100% EOU Scheme in Karnataka.
• 2001-02: Top Exporter Sector - Biotechnology; 100% EOUs in Karnataka; Ptd by Cochin Special Economic Zone, Govt of India, Ministry of Commerce & Industry.
• 2005: BioSpectrum Bio Services Company of the Year.
• 2007: BioSpectrum Bio Services Company of the Year.
• 2008: 'Bangalore Bio' Bio Excellence Award - Biotech Services Sector.
• 2008: BioSpectrum Bio Services Company of the Year.
• 2009: 'Bangalore Bio' Bio Excellence Award - Biotech Services Sector.
• 2009: Best Bioservices Company of the Year- by Biospectrum.
• 2011: CIO100 Award.
• 2011: 'Workplace Assessment Conditions (WCA) Achievement Award' by Intertek.
• 2011: 'Sliver EDGE' Award - Enterprise Driving Growth & Excellence Through IT.
• 2012: CIO100 Award for highest level of operational and strategic excellence in information technology.
• 2013: ABLE (Association of Biotechnology Led Enterprises) - Tenth Anniversary Award for ‘Outstanding contribution to Bioservices’.
• 2013: Diamond Sponsor-Recognation by the Association of Scientists of Indian Origin of the Society of Toxicology.
• 2014: 'Sliver EDGE' Award - Enterprise Driving Growth & Excellence Through IT for ‘Comprehensive SAP Implementation’.
• 2014: EHS best practices award by CII.
• 2014: SAP Ace Award for special recognition for complex SAP implementation.
• 2014: Level I Laboratory certification issued by the NGSP to Clinigene International Limited.
• 2014: SAP ACE Award 2014 won by Syngene RISE team.
• 2015: Organisation with Innovative HR Practices Award - At the 14th Annual Asia Pacific HRM Congress 2015.
• 2015: CIO100 Award 2015 - The Versatile Honoree Award & The CIO 100 Networking Pioneer Special Award.
• 2015: Bangalore India Bio - Bio Excellence Award for outstanding contribution to the Biotech services sector.
• 2016: Dynamic Enterprise of the Year 2016 - At the 9th Annual Pharmaceutical Leadership Summit & Pharma Leaders Business Leadership Awards 2016- in recognition for its contribution to the field of Research and Development for the Life Science Industry.
• 2016: CII Award - Won first place in the Office/Software/Service Sector.
• 2016: CII Award- Four Star Rating on Environment Health & Safety Management System.
• 2017: Best Contract Research Organisation (CRO) Provider - Runner-up Award - At The 4th Annual World ADC Awards 2017.
• 2017: Bio Services Excellence Award 2017 - Bangalore Tech Summit.
• 2018: Bio-Excellence Award 2018 - At Bengaluru Tech Summit, Bengaluru.
• 2018: Best Bioprocessing Excellence Award 2018 - At 5th Biologics Manufacturing Asia, Singapore.
• 2018: Healthcare Company of the Year 2018- At the 7th Annual VCCircle Awards 2018, Mumbai.
• 2018: HR Excellence Award 2018 'For Best Talent Management Strategy' - At the HR Talent Management Leadership Awards (World HRD Congress), Mumbai.
• 2019: Best Employer Brand 2019 by the Employer Branding Institute, World HRD Congress at the 14th edition of the awards for robust and effective HR and people management system.
• 2019: India Pharma Award 2019 - For “Excellence in Contract Research and Manufacturing Services” at CPhI & P-MEC India Expo.
• 2019: Utthama Suraksha Puraskar 2019 - (Pharma and Chemical Manufacturing Category) by National Safety Council of India (NSCI). Leadership Awards.
• 2019: CMO Leadership Awards- Presented by Life Science Leader Magazine in New York.
• 2019: FICCI CSR Award for Environmental Sustainability - At the 17th Edition of the awards in New Delhi.
• 2019: Safe Workplace Champion Award - At the 8th Manufacturing Supply Chain Summit and Awards.
• 2019: Best Leadership Development Program for Middle Management Award - At the 6th Global Training and Development Leadership Awards.
• 2020: ASSOCHAM CSR and NGO Awards 2020 for COVID-19 Response
• 2020: CMO Leadership Award 2020
• 2020: Bioprocessing Excellence Award 2020
• 2021: Mahatma Award 2021 under Health & Wellbeing category
• 2021: Best Corporate Foundation Award 2021.
• 2021: Best Governed Company in the Medium Category for 2021.
• 2021: Most Innovative New Learning Programme Award 2021.
• 2021: Ranked as one of the Top 100 Indian wealth creators for 2021 by the Fortune India magazine.
• 2021: Asian Leadership Award 2021.
• 2022: Pharmaceutical Technology Excellence Ranking 2022.
• 2022: Winner of the CII National Energy Efficiency Circle Competition 2022.
• 2022: The Brandon Hall Group HCM Excellence Bronze Award in Leadership Development 2022.
• 2022: Golden Peacock Award 2022.
• 2022: Biopharma Honours Award 2022.
• 2023: India Sustainability Conclave & Awards, 2023.
• 2023: Quality Circle Forum of India Awards, 2023.
• 2023: The Brandon Hall Group HCM Excellence Gold Award in Learning and Development 2023.
• 2023: Golden Peacock National Quality Award, 2023.
• 2023: Biopharma Excellence Award (India Edition) 2023.
• 2024: Asia Pacific Biologics CMO Excellence Awards 2024.
• 2024: EcoVadis Sustainability Rating, 2024.
• 2024: CDMO Leadership Awards 2024.
• 2025: Pharma Supply Chain Champion (mid-sized firms) 2025.
• 2025: World's Most Sustainable Companies, 2025.
• 2025: CDMO Leadership Award 2025.
• 2025: Biopharma Excellence Awards 2025 (India Edition).

Milestones

• 1994: Initiated operations as a CRO with services in chemistry and biology.
• 1998: Granted 100% Export Oriented Unit (EOU) status by the Government of India.
• 1999: First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
• 2000: Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
• 2001: Forayed into chemical development with a dedicated manufacturing facility.
• 2003: Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft. 
• 2007: Bristol-Myers Squibb and the Company signed the first long-term contract to set up its first dedicated R&D Center.
• 2007: Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
• 2007: Crossed an annual turnover of over Rs 1,000 million in Financial Year 2007.
• 2009: Dupont Crop Protection and the Company extended a partnership for R&D services.
• 2009: Expansion of manufacturing services with a new plant which is cGMP compliant.
• 2009: Initiated operations in safety assessment and large molecules development services.
• 2010: Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
• 2010: Initiated operations in formulation development.
• 2011: Endo Pharmaceuticals and the Company collaborated to develop novel biological therapeutic molecules against cancer.
• 2012: Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and its second dedicated R&D center.
• 2012: Certification of clinical facilities by ANVISA.
• 2012: Acquired 100% stake in Clinigene International Limited from Biocon.
• 2013: Crossed an annual turnover of over Rs 5,000 million in Financial Year 2013.
• 2013: Crossed an annual turnover of over Rs 5,000 million in Financial Year 2013.
• 2013: Acceptance of its control testing laboratory by the Department of Health & Human Services, FDA.
• 2014: Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020.
• 2014: Acceptance of manufacturing facility by the Department of Health & Human Services, FDA.
• 2014: Established a 75,000 sq.ft center to provide stability and analytical services.
• 2015: Syngene listed on BSE (Bombay Stock Exchange) & NSE (National Stock Exchange) of India
• 2015: Clinigene International Limited amalgamated with Syngene.
• 2016: Acquisition of Strand Life Sciences’ Systems Biology and Pharma Services Practice Assets: Expansion into Bioinformatics & NGS Services.
• 2016: Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, its fourth dedicated R&D center.
• 2016: Crossed an annual turnover of Rs 10,000 Million.
• 2017: Strategic collaboration with Zoetis to develop and manufacture animal medicines.
• 2017: Herbalife Nutrition collaborated with Syngene to establish its first nutrition research & development center in India.
• 2017: Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
• 2017: Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
• 2018: Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas.
• 2018: Received PMDA Accreditation.
• 2018: Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services.
• 2018: Syngene expands collaboration with Baxter until 2024.
• 2019: Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS).
• 2019: cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function.
• 2020: Commenced Phase I operations at Hyderabad.
• 2020: GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider).
• 2020: COVID-19: Setting up of RT-PCR testing center.
• 2020: Successfully completed unannounced US FDA inspection for Bio-analytical studies.
• 2020: Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy.
• 2020: Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order.
  
• 2021: Syngene International extends long term research collaboration with Bristol Myers Squibb until 2030.
• 2021: Syngene announces senior-level appointments Strengthens leadership in USA.
• 2021: Syngene expands biopharma-manufacturing capacity. Sets up a state-of-the-art microbial facility; expands mammalian facility.
• 2021: Syngene through Biocon Foundation partners with NIMHANS for BHUMI.
• 2021: Syngene International Announces Extension of Collaboration with Amgen.
• 2022: Syngene releases its first ESG report for FY2020-21 in accordance with the Global Reporting Initiative (GRI).
• 2022: Syngene signs 10-year biologics manufacturing agreement with leading animal health company, Zoetis.
• 2023: Syngene purchases land to expand operations in Genome Valley, Hyderabad.
• 2023: Syngene concludes the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd.
• 2024: Syngene launches platform for rapid, enhanced protein production.
• 2024: Syngene achieves silver in EcoVadis ESG assessment.
• 2025: Syngene Acquires its First Manufacturing Facility in the US.
• 2025: Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.
• 2025: Syngene International invests in dedicated peptide laboratory and advanced automation.
• 2026: Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035.
• 2026: Syngene Collaborates with Johns Hopkins University to Advance Early-Stage Drug Discovery.